Skip to Content
  • Abstract
  • Open Access

11 January 2021

2 Pages

The Clinical Potential of Point-of-Care Quantitative Spectrochip Coupled with Lateral Flow Immunoassay during the COVID-19 Pandemic †

,
,
and
1
Department of Emergency Medicine, Mackay Memorial Hospital, Taipei 104217, Taiwan
2
Graduate Institute of Automation and Control, National Taiwan University of Science and Technology, Taipei 10607, Taiwan
3
Department of Pediatrics and Medicine, Stanford University School of Medicine, Stanford, CA 291, USA
4
Department of Pediatrics, Taipei Hospital, Ministry of Health and Welfare, New Taipei City 242, Taiwan

Abstract

Coronavirus disease (COVID-19) is a large-scale global public health challenge that still persists. A method that achieves the rapid quantitative detection of antibodies to assess the body’s immune response from a natural COVID-19 illness or the vaccines’ effects is urgently needed. In the present study, we integrated a newly designed spectrometer with COVID-19 test strip procedures; this augmentation provides the capacity for a lateral flow immunoassay (LFIA) to be quantitative. Optical interpretation of results by quantitative α index was undertaken, rather than visual qualification. It can be performed quickly in 5–10 min. We compared the developed product with several other serological IgM/IgG antibody reagents on the market by recruiting 111 participants with a suspected COVID-19 infection from March to May 2020 in a single hospital. Taking RT-PCR as the diagnostic gold standard, the quantitative spectral LIFA platform could detect all 12 COVID-19 patients correctly (100% sensitivity, 12/12). In contrast, the sensitivity for ACE Biolab alone is 91.67% (11/12), and for Biomedomics, it is 58.33% (7/12). Methods that use Nucleocapsid (N) + Spike (S) solid-phase antigen (i.e., ACE Biolab, TBG, and Spectrochip +ACE Biolab) perform better compared with those that use Nucleocapsid (Biomedomics) or Spike (ASK) alone. Concerning negative RT-PCR patients, all three antibody testing methods found positive cases. The optical-based platform exhibited the ability of the early detection of immunoglobulins of negative RT-PCR patients. There was an apparent trend of an elevation of IgM levels in the acute phase of infection, then the IgG levels rose again later. It exhibited the risk of a false-negative diagnosis of RT-PCR in COVID-19 testing. The significant detection ability of this new optical-based platform demonstrated clinical potential.

Author Contributions

Conceptualization, I.-J.W.; formal analysis, C.-H.K.; writing—P.-Y.C. and I.-J.W.; writing—review and editing, C.J.W. and I.-J.W.; supervision, I.-J.W. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Taipei Hospital Ministry of Health and Welfare, and the Ministry of Science and Technology in Taiwan (MOST 109-2628-B-192-001)

Institutional Review Board Statement

The present study was approved by the Joint Institutional Review Board (JIRB) of the Taipei Hospital, Ministry of Health and Welfare (IRB numbers: TH-IRB-0020-0011).

Data Availability Statement

All relevant data are within the manuscript and its Supporting information files.

Conflicts of Interest

There is no conflict of interest.
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.